Qyuns Therapeutics Buys Back 174,400 H-Shares, Expands Treasury Stock to 2.88 Million Shares

Bulletin Express06-01

Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share-repurchase transaction conducted on 1 June 2026 under its Hong Kong Stock Exchange mandate approved on 29 May 2026.

• Transaction details – Volume repurchased: 174,400 H-shares, now held as treasury stock. – Price range: HKD 15.66 to HKD 16.54 per share, with a volume-weighted average of HKD 16.14. – Aggregate consideration: HKD 2.81 million.

• Capital structure impact – Issued shares outstanding (excluding treasury shares) decreased to 224.19 million from 224.36 million, a reduction of 0.08%. – Treasury shares rose to 2.88 million from 2.71 million. – Total issued shares remained unchanged at 227.07 million.

• Repurchase capacity – The current mandate authorises buybacks of up to 22.44 million shares; the latest transaction utilises 0.78% of that limit. – A 30-day moratorium on new share issues or treasury-share disposals runs through 1 July 2026, in line with HKEX Rule 10.06(3).

The company confirmed that the repurchase complied with Main Board requirements and that no material changes have been made to the explanatory statement filed on 8 May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1100751279?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 21:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100751279","market":"us","top_or_hot":-1,"title":"Qyuns Therapeutics Buys Back 174,400 H-Shares, Expands Treasury Stock to 2.88 Million Shares","media":"Bulletin Express","content":"<p>Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share-repurchase transaction conducted on 1 June 2026 under its Hong Kong Stock Exchange mandate approved on 29 May 2026.</p>\n<p>• Transaction details  \n  – Volume repurchased: 174,400 H-shares, now held as treasury stock.  \n  – Price range: HKD 15.66 to HKD 16.54 per share, with a volume-weighted average of HKD 16.14.  \n  – Aggregate consideration: HKD 2.81 million.</p>\n<p>• Capital structure impact  \n  – Issued shares outstanding (excluding treasury shares) decreased to 224.19 million from 224.36 million, a reduction of 0.08%.  \n  – Treasury shares rose to 2.88 million from 2.71 million.  \n  – Total issued shares remained unchanged at 227.07 million.</p>\n<p>• Repurchase capacity  \n  – The current mandate authorises buybacks of up to 22.44 million shares; the latest transaction utilises 0.78% of that limit.  \n  – A 30-day moratorium on new share issues or treasury-share disposals runs through 1 July 2026, in line with HKEX Rule 10.06(3).</p>\n<p>The company confirmed that the repurchase complied with Main Board requirements and that no material changes have been made to the explanatory statement filed on 8 May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Qyuns Therapeutics Buys Back 174,400 H-Shares, Expands Treasury Stock to 2.88 Million Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQyuns Therapeutics Buys Back 174,400 H-Shares, Expands Treasury Stock to 2.88 Million Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-01 21:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share-repurchase transaction conducted on 1 June 2026 under its Hong Kong Stock Exchange mandate approved on 29 May 2026.</p>\n<p>• Transaction details  \n  – Volume repurchased: 174,400 H-shares, now held as treasury stock.  \n  – Price range: HKD 15.66 to HKD 16.54 per share, with a volume-weighted average of HKD 16.14.  \n  – Aggregate consideration: HKD 2.81 million.</p>\n<p>• Capital structure impact  \n  – Issued shares outstanding (excluding treasury shares) decreased to 224.19 million from 224.36 million, a reduction of 0.08%.  \n  – Treasury shares rose to 2.88 million from 2.71 million.  \n  – Total issued shares remained unchanged at 227.07 million.</p>\n<p>• Repurchase capacity  \n  – The current mandate authorises buybacks of up to 22.44 million shares; the latest transaction utilises 0.78% of that limit.  \n  – A 30-day moratorium on new share issues or treasury-share disposals runs through 1 July 2026, in line with HKEX Rule 10.06(3).</p>\n<p>The company confirmed that the repurchase complied with Main Board requirements and that no material changes have been made to the explanatory statement filed on 8 May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1100751279","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100751279","pubTimestamp":1780321441,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share-repurchase transaction conducted on 1 June 2026 under its Hong Kong Stock Exchange mandate approved on 29 May 2026. • Transaction details...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B"},"translate_title":"Qyuns Therapeutics回购17.44万股H股，库存股扩大至288万股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a share-repurchase transaction conducted on 1 June 2026 under its Hong Kong Stock Exchange mandate approved on 29 May 2026.\n• Transaction details  \n  – Volume repurchased: 174,400 H-shares, now held as treasury stock.  \n  – Price range: HKD 15.66 to HKD 16.54 per share, with a volume-weighted average of HKD 16.14.  \n  – Aggregate consideration: HKD 2.81 million.\n• Capital structure impact  \n  – Issued shares outstanding (excluding treasury shares) decreased to 224.19 million from 224.36 million, a reduction of 0.08%.  \n  – Treasury shares rose to 2.88 million from 2.71 million.  \n  – Total issued shares remained unchanged at 227.07 million.\n• Repurchase capacity  \n  – The current mandate authorises buybacks of up to 22.44 million shares; the latest transaction utilises 0.78% of that limit.  \n  – A 30-day moratorium on new share issues or treasury-share disposals runs through 1 July 2026, in line with HKEX Rule 10.06(3).\nThe company confirmed that the repurchase complied with Main Board requirements and that no material changes have been made to the explanatory statement filed on 8 May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1100751279","isCrawlerRequest":true}